Retatrutide Dosage Guide: Starting Dose, Titration & Protocol

The standard retatrutide dosage starts at 2mg once weekly and titrates up to a maximum of 12mg per week following a 4-week escalation schedule. Every dose increase happens every four weeks, giving your body time to adapt before moving higher.

What Is Retatrutide and Why Does Dosing Matter So Much?

Retatrutide (LY3437943) is a triple-agonist peptide that activates three metabolic receptors simultaneously: GLP-1, GIP, and glucagon. That third receptor — glucagon — is what sets it apart from tirzepatide and semaglutide. It ramps up energy expenditure and accelerates fat breakdown in ways the dual and single agonists can't match.

If you want the full background on the mechanism, read our guide on what retatrutide is and how it works.

Dosing matters with retatrutide more than almost any other peptide in this class. Titrate too fast and you'll hit serious GI side effects that make the whole protocol miserable. Titrate too slowly and you delay results. The protocol below is pulled directly from the TRIUMPH Phase 2 trial data published in the New England Journal of Medicine — real numbers, not guesswork.

The Standard Retatrutide Titration Protocol

The titration schedule used in the TRIUMPH Phase 2 clinical trial is the closest thing to an evidence-based protocol available right now. Every 4 weeks, the dose steps up — but only if the current dose is being tolerated well.

Source: TRIUMPH Phase 2 Trial, NEJM 2023 (NCT04881760)

Why Every 4 Weeks?

Retatrutide has a half-life of approximately 6 days, which means it takes roughly 4–5 weeks to reach a true steady-state plasma concentration at any given dose. Increasing before steady state is reached means you're stacking doses before your body has fully adapted — that's the formula for nausea, vomiting, and dropping out of the protocol entirely.

Starting Dose of Retatrutide: 2mg Weekly

The starting dose is 2mg subcutaneous injection once per week. At this dose, you're not going to see dramatic weight loss — and that's intentional. Week 1–4 is about establishing baseline tolerance, confirming there are no adverse injection site reactions, and letting your GI system begin adapting to triple-receptor activation.

What to Expect in Weeks 1–4

• Mild appetite reduction (usually noticeable by days 2–3 post-injection)
• Possible light nausea, especially after high-fat or large meals
• Minor injection site redness or swelling — normal and usually resolves within 24 hours
• Weight loss: expect 0–2 lbs during this phase; the 2mg dose is not the workhorse

The TRIUMPH trial's 2mg arm did not show significant standalone weight loss, which is exactly why this phase exists — tolerability, not results.

Where to Inject

Subcutaneous injection into the abdomen, upper thigh, or outer upper arm. Rotate sites each week to prevent lipohypertrophy (fat buildup under the skin). Never inject into the same spot twice in a row.

Retatrutide Dosage for Adults: Full Week-by-Week Breakdown

Here's the week-by-week picture of what the protocol looks like in practice:

Weight loss figures are estimates based on TRIUMPH Phase 2 trial data. Individual results vary.

TRIUMPH Phase 2 Trial Data: What the Numbers Actually Show

The TRIUMPH Phase 2 trial is the primary clinical evidence for retatrutide dosing. Published in the NEJM in 2023, this was a 48-week randomized, placebo-controlled trial involving 338 participants with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

Key Results by Dose Group

The 12mg group achieved a mean weight loss of 24.2% of baseline body weight at 48 weeks — the highest ever recorded in a GLP/GIP-class clinical trial at the time of publication. To put that in perspective: someone starting at 250 lbs could expect to lose approximately 60 lbs over 48 weeks on the maximum dose.

The 8mg group's results were nearly as strong at 22.8%, which is why many protocols suggest that 8mg is a reasonable maintenance dose for most people rather than pushing to 12mg.

Dose Escalation: When to Move Up (and When to Stay Put)

Criteria for Moving to the Next Dose

You can proceed to the next dose level after 4 weeks only if:

• GI side effects (nausea, vomiting, diarrhea) have resolved or are minimal
• You're not experiencing persistent injection site reactions
• No signs of dehydration or nutritional deficiency
• Weight loss rate is steady but not dangerously rapid (>3–4 lbs/week consistently suggests the current dose may already be working well)

When to Hold the Current Dose

Delay escalation and stay at your current retatrutide dose if:

• Nausea or vomiting is still occurring more than 3 days after injection day
• Severe GI discomfort is disrupting daily function
• You've lost more than 4 lbs in the past week without trying — your current dose may be plenty
• You're dealing with fatigue or dizziness that hasn't stabilized

Staying at 8mg instead of pushing to 12mg is a completely valid long-term strategy. The trial data shows a strong response at 8mg, and many find the incremental benefit of 12mg isn't worth the additional side effect burden.

Retatrutide Maintenance Dose

Once you've reached your target dose and weight loss has stabilized, you enter the maintenance phase. This typically happens at either 8mg or 12mg per week, depending on your individual response and tolerance.

Characteristics of the Maintenance Phase

• Weight loss slows but continues — total body weight tends to stabilize around week 40–52
• GI side effects that appeared during escalation typically fully resolve
• Appetite suppression remains strong and consistent
• Injection day becomes routine, with predictable effects

Some protocols describe a "dose reduction" phase after reaching goal weight — stepping back down to 8mg or even 4mg to maintain results with a lower side effect profile. There's no clinical trial data specifically on this reduction approach yet, but it follows the same logic as other GLP-1 class maintenance protocols.

Missed Dose: What to Do

Retatrutide's long half-life (~6 days) gives you a reasonable window to catch a missed dose, but there are firm rules:

Missed Dose Protocol

• Missed by 4 days or less: Take the missed dose as soon as you remember, then resume your regular weekly schedule
• Missed by more than 4 days: Skip the missed dose entirely and wait until your next regularly scheduled injection day
• Never double-dose: Taking two doses to catch up increases side effect risk significantly and can cause dangerous GI reactions

Setting Up a Routine

Because retatrutide is once-weekly, the easiest way to avoid missed doses is to anchor it to a fixed day and time — Sunday morning before breakfast, for example. Many people take their injection on the same day they do a weekly weight check to create a consistent habit.

Dose Adjustments: Reducing or Pausing

Life happens. There are situations where you may need to reduce your dose or pause the protocol entirely.

Reasons to Step Back Down

• Surgery or procedure requiring fasting — pause 1–2 weeks before
• Severe illness causing vomiting or dehydration — hold current dose
• Pregnancy (discontinue immediately and consult a physician)
• Side effects that are genuinely unmanageable at current dose — reduce by one level and re-try escalation in 4–8 weeks

Returning After a Break

If you pause for more than 2–4 weeks, most protocols recommend restarting at a lower dose rather than picking back up where you left off. A 2-week break generally requires restarting at the previous dose level; breaks longer than 4 weeks often mean restarting from 2mg. This mimics the re-titration approach used in semaglutide and tirzepatide protocols.

Retatrutide Weekly Dose: Practical Injection Guide

Injection Technique

1. Remove the vial from refrigeration 15–30 minutes before injection to bring it to room temperature
2. Draw the correct volume based on your vial's concentration (see the retatrutide dosage chart for volume-to-dose conversions)
3. Clean the injection site with an alcohol swab and allow to dry
4. Pinch the skin gently; insert the needle at a 45° angle for lean individuals, 90° for more body fat
5. Inject slowly — over 5–10 seconds to minimize discomfort
6. Remove the needle and apply light pressure; do not rub
7. Dispose of the needle in a sharps container

Common Vial Concentrations and Dosing Volumes

Always verify your specific vial's concentration before drawing. Miscalculating concentration is the most common dosing error.

Managing Side Effects During Titration

Most side effects with retatrutide are GI in nature and peak during the first 1–2 weeks after each dose increase. They typically resolve as your body adjusts.

Most Common Side Effects by Phase

For the full side effect profile with management strategies, read the retatrutide side effects guide.

Practical Side Effect Mitigation

• Timing: Take your injection in the evening so peak nausea (typically 12–24 hours later) happens overnight
• Food: Eat smaller, lower-fat meals on injection day and the day after
• Hydration: Increase water intake — dehydration makes GI symptoms significantly worse
• Anti-nausea support: Ginger tea, peppermint, or over-the-counter antiemetics can help during transition periods

Conservative Titration: For Sensitive Individuals

Some people are more sensitive to GLP/GIP-class medications. If you've had severe GI reactions to semaglutide or tirzepatide in the past, a more conservative titration may be appropriate:

This extends the total protocol by 8+ weeks but significantly reduces GI burden for sensitive individuals. The trade-off is a delayed timeline to therapeutic results.

Where to Source Retatrutide

Retatrutide is not yet FDA-approved and remains in Phase 3 trials. Prescription access via a licensed compounding pharmacy or clinical trial enrollment are the legitimate pathways.

For high-quality retatrutide, Ascension Peptides is a trusted source with documented purity testing and consistent concentrations. Always verify third-party testing certificates before purchasing any peptide.

Medical Disclaimer

The information in this article is for educational purposes only and does not constitute medical advice. Retatrutide is not FDA-approved and should only be used under the guidance of a qualified healthcare provider. Dosing information is based on published Phase 2 clinical trial data and may not apply to every individual. Always consult a licensed physician before starting, adjusting, or stopping any peptide or medication protocol. Report any adverse effects to your healthcare provider immediately.